In "Factors Associated with Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial," by Li et al. (J Infect Dis. (2011) 203 (7): 976–983), the title of Table 2 was inadvertently changed and some data were incorrect due to errors made without the authors' knowledge. A corrected version of the table is shown below.

Table 2. Number of log_{10} Gag-Specific CD4+ IFN- γ -Producing Cells per Million Lymphocytes at Study Week 38 Categorized by HLA Allele Grouping and Treatment Arm

HLA group	P ^b	Treatment arm, median [IQR] ^a		
		Vaccine	Placebo	P ^c
Protective	.10	2.21 [± 0.70] (n=31)	2.25 [± 0.43] (n=5)	
Neutral		2.40 [± 0.40] (n=36)	2.11 [± 0.51] (n=27)	.003
Unfavorable		2.1 [± 0.51] (n=5)	2.17 [± 1.40] (n=4)	

NOTE. ^a IQR, interquartile range.

^b Comparison of the vaccine/protective and vaccine/neutral subgroups.

^c Comparison of the vaccine/neutral and placebo/neutral subgroups.

The Journal of Infectious Diseases 2011;204:664

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011. 0022-1899 (print)/1537-6613 (online)/2011/2044-0024\$14.00 DOI: 10.1093/infdis/jir384